Sermorelin Acetate (5mg)

Sermorelin is a synthetic 29-amino-acid peptide representing the biologically active N-terminal fragment of endogenous Growth Hormone-Releasing Hormone (GHRH). It is the shortest GHRH fragment that retains full binding affinity and biological activity at GHRH receptors on pituitary somatotrophs, making it the most clinically validated GHRH analog in research.

Sermorelin binds GHRH receptors to activate adenylate cyclase, elevate intracellular cAMP, and trigger pulsatile GH secretion from anterior pituitary somatotrophs. Critically, unlike exogenous recombinant GH (rhGH), Sermorelin preserves the natural GH feedback axis — somatostatin and IGF-1 continue to regulate GH release, preventing runaway GH elevation and maintaining physiological pulsatility. This makes Sermorelin considerably safer and more physiologically appropriate than direct GH administration for research protocols requiring GH axis stimulation.

Originally FDA-approved for paediatric GH deficiency (Geref®), Sermorelin is extensively studied in adults for age-related GH decline, body composition improvement, sleep quality enhancement, and metabolic support. Its bedtime administration leverages the natural nocturnal GH pulse — peak GH secretion occurs during slow-wave sleep — for maximum physiological relevance.